Brief: Crossject Engages Syneos Health For U.S. Commercial Launch Of Zepizure
04/01/2024 17:00
Jan 4 (Reuters) - Crossject SA 74C.F :
* REG-CROSSJECT ENGAGES SYNEOS HEALTH FOR U.S. COMMERCIAL
LAUNCH
OF ZEPIZURE®
Source text for Eikon: ID:nGNE4ByfgF
Further company coverage: 74C.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crossject SA
See all newsBrief: Crossject Says Expects To File For EUA Early Next Year For Epilepsy Rescue Therapy Zepizure
Brief: Crossject Signs A Geographic Extension Of Zepizure Commercialization Agreement In Europe
Brief: Crossject FY Operating Income Up At EUR 12.82 Mln
Brief: Crossject Announces Contract Of Up To $155 Mln With BARDA
Brief: Crossject Engages Syneos Health For U.S. Commercial Launch Of Zepizure